First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people with advanced non-squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 status, results from a Phase 1/2 trial show. Compared with platinum-based chemotherapy alone, the combo treatment also led to higher response rates in these patients, whose tumors contained no mutations in the EGFR or ALK genes. These are the four-year follow-up results of…
You must be logged in to read/download the full post.
The post Keytruda-Chemo Combo Improves Survival Outcomes in Advanced Lung Cancer appeared first on BioNewsFeeds.